RE: yes, can we13 Nov 2018 21:47
Theobald said the firm’s next research study would focus on demonstrating the ability of Nuvec to deliver an effective level of immunity using OVA, the results of which would be available in the first half of 2019.
“We are pleased with the Nuvec results received to date and will continue to focus on the many opportunities that we believe will exist for Nuvec to be used to develop a range of different vaccines and cancer treatments.
“We are building a compelling data package to aide our commercial collaboration discussions which we continue to progress.”